Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for ...

The antisense oligonucleotide is a prophylactic treatment for preventing swelling attacks due to hereditary angioedema.

In Ionis Pharmaceuticals Inc.’s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and genetic disease hereditary angioedema ...

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

Dawnzera, a prekallikrein-directed antisense oligonucleotide, is supplied as a 80mg/0.8mL solution in a single-dose autoinjector.

Developed by Ionis Pharmaceuticals, Dawnzera is the first RNA-targeted medicine approved for HAE, designed to target plasma ...

BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $64 from $63 and keeps a Buy rating on the shares ...

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

The drug, Dawnzera, is approved to prevent symptoms of a rare genetic disease called hereditary angioedema (HAE) in adults ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition, and the second wholly owned medicine Ionis has brought to market.